3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Small Cell
1
Interventions
Rituximab
90
Cyclophosphamide
30
Lenalidomide
28
Bendamustine Hydrochloride
24
Prednisone
20
Vincristine
19
obinutuzumab
17
Doxorubicin
16
fludarabine
14
ibrutinib
13
tazemetostat
9
idelalisib
9
Deoxycholic Acid
9
parsaclisib
8
Prednisolone
8
zanubrutinib
7
venetoclax
7
tofacitinib
7
tisagenlecleucel
5
pembrolizumab
5
ofatumumab
5
ibritumomab tiuxetan
5
duvelisib
5
Gemcitabine
5
Bortezomib
5
durvalumab
4
aflibercept
4
R-CHOP protocol
4
Methylprednisolone
4
Methotrexate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Follicular
×
etoposide phosphate
×
Clear all
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled